UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Reduces Holdings in Bio-Rad Laboratories, Inc. $BIO

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 1.5% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 382,807 shares of the medical research company’s stock after selling 5,820 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 1.37% of Bio-Rad Laboratories worth $93,236,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its holdings in Bio-Rad Laboratories by 17.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 877,040 shares of the medical research company’s stock valued at $213,608,000 after buying an additional 130,921 shares in the last quarter. Ariel Investments LLC grew its holdings in Bio-Rad Laboratories by 29.3% in the 1st quarter. Ariel Investments LLC now owns 724,660 shares of the medical research company’s stock valued at $176,498,000 after buying an additional 164,136 shares in the last quarter. First Pacific Advisors LP grew its holdings in Bio-Rad Laboratories by 136.0% in the 1st quarter. First Pacific Advisors LP now owns 372,555 shares of the medical research company’s stock valued at $90,739,000 after buying an additional 214,705 shares in the last quarter. Parnassus Investments LLC grew its holdings in Bio-Rad Laboratories by 2.3% in the 1st quarter. Parnassus Investments LLC now owns 318,111 shares of the medical research company’s stock valued at $77,479,000 after buying an additional 7,244 shares in the last quarter. Finally, Mawer Investment Management Ltd. grew its holdings in Bio-Rad Laboratories by 14.8% in the 1st quarter. Mawer Investment Management Ltd. now owns 294,879 shares of the medical research company’s stock valued at $71,821,000 after buying an additional 37,952 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Wells Fargo & Company upped their target price on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Friday, August 22nd. Royal Bank Of Canada increased their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Finally, Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $333.50.

Bio-Rad Laboratories Price Performance

BIO stock opened at $280.32 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The firm has a market capitalization of $7.59 billion, a P/E ratio of 23.90 and a beta of 0.95. The business’s 50-day moving average is $272.32 and its two-hundred day moving average is $251.90. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The business had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same quarter in the prior year, the business posted $3.11 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.